Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TOP2A | P11388 | 1/20 | 0.51 |
| ▸ | SRC | P12931 | 6/20 | 0.50 |
| ▸ | POLH | Q9Y253 | 5/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | MMP1 | P03956 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | APEX1 | P27695 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | RECQL | P46063 | 1/20 | 0.46 |
| ▸ | BLM | P54132 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21621478 | 1.00 | TOP2A (0.51) | TOP2ASRCPOLHKDM4EMEN1 | |
| SCHEMBL21621463 | 0.95 | POLH (0.52) | TOP2ASRCPOLHKDM4EMEN1 | |
| SCHEMBL23326103 | 0.94 | POLH (0.51) | TOP2ASRCPOLHKDM4EMEN1 | |
| SCHEMBL21621460 | 0.94 | POLH (0.51) | TOP2ASRCPOLHKDM4EMEN1 | |
| SCHEMBL23353534 | 0.92 | TOP2A (0.45) | TOP2ASRCPOLHKDM4EMEN1 | |
| SCHEMBL21621466 | 0.91 | TOP2A (0.51) | TOP2ASRCPOLHKDM4EMEN1 | |
| SCHEMBL23353535 | 0.88 | TOP2A (0.44) | TOP2ASRCPOLHKDM4EMEN1 | |
| SCHEMBL21621461 | 0.86 | POLH (0.51) | TOP2ASRCPOLHKDM4EMEN1 | |
| SCHEMBL21621468 | 0.86 | POLH (0.64) | TOP2ASRCPOLHKDM4EMEN1 | |
| SCHEMBL4163481 | 0.85 | POLH (0.65) | TOP2ASRCPOLHKDM4EMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12195437-B2 | Lipophenolic flavonoid derivatives useful to reduce carbonyl and oxidative stresses (COS) | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) | 2025-01-14 | — | — | US | disclosed |
| US-20210139447-A1 | Lipophenolic Flavonoid Derivatives Useful To Reduce Carbonyl And Oxidative Stresses (COS) | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) | 2021-05-13 | — | — | US | disclosed |
| US-20210139447-A1 | Lipophenolic Flavonoid Derivatives Useful To Reduce Carbonyl And Oxidative Stresses (COS) | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) | 2021-05-13 | — | — | US | disclosed |
| CN-112739688-A | Liposol flavone derivatives useful for reducing carbonyl stress and oxidative stress (COS) | 国家科学研究中心 | 2021-04-30 | — | — | CN | disclosed |
| WO-2020012003-A1 | LIPOPHENOLIC FLAVONOID DERIVATIVES USEFUL TO REDUCE CARBONYL AND OXIDATIVE STRESSES (COS) | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) | 2020-01-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12195437-B2 | Lipophenolic flavonoid derivatives useful to reduce carbonyl and oxidative stresses (COS) | LPO, NQO1, CAT | TOP2A 674/4885SRC 3798/4885POLH 1787/4885 |
| US-20210139447-A1 | Lipophenolic Flavonoid Derivatives Useful To Reduce Carbonyl And Oxidative Stresses (COS) | LPO, NQO1, CAT | TOP2A 674/4885SRC 3798/4885POLH 1787/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.